Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-NOW: Orforglipron in adults with overweight at risk of obesity-related complications
2026-526175-35-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Overweight, prediabetes and prehypertension comparing Orforglipron with Placebo (2 arms). Primary endpoint: Time to Onset of Obesity Related Complications or Class 1 Obesity. Planned start Oct 2026; status: authorised.
02
Drugs
orforglipron
03
Conditions
Overweightprediabetesprehypertension
Beyond the preview
Go deeper on 2026-526175-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526175-35-00.